Tipranks Press Release.
Aclaris (ACRS) delivered earnings and revenue surprises of +25.00% and +16.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY. A live and archived webcast of this event will be accessible on
Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $10.58, according
This is the newest page. Registered accounts read further back.